A panel of FDA advisers voted in favor of Replimune’s oncolytic melanoma therapy RP1 when used in combination with a PD-1 inhibitor, signaling improved odds for approval after prior submissions were rejected. In the meeting, panelists concluded the pivotal efficacy results were evaluable and clinically meaningful, despite FDA scientists’ concerns about trial design and interpretability.